Watchlist

Watchlist
Amicus Therapeutics, Inc. (FOLD)
Amicus Therapeutics, Inc. (FOLD)
Institutional Top Ideas Series: Perceptive Advisors
In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds …
Is Amicus On The Verge Of A Breakout?
Amicus Therapeutics ( FOLD ) is dedicated to the development and marketing of drugs for rare and orphan conditions: Our strategy is to create, manufacture, test and deliver the highest quality medicines for people living with rare metabolic diseases through internally developed, acquired …
Protalix: Valuable, Misunderstood, And Deeply Mispriced
Editor's note: Seeking Alpha is proud to welcome The Sensible Steward as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Abo…
Amicus Therapeutics, Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2018 Q1 earnings Read more …
Amicus Therapeutics' (FOLD) CEO John Crowley on Q1 2018 Results - Earnings Call Transcript
Amicus Therapeutics, Inc. (FOLD) Q1 2018 Earnings Conference Call May 08, 2018 08:30 AM ET Executives Sara Pellegrino - Vice President of Investor Relations and Corporate Communications John Crowley - Chairman and Chief Executive Officer Bradley Campbell - President and Chief Ope…
Premarket Losers as of 9:05 am (5/8/2018)
ARLZ -26% on terminating U.S. operations. More news on: Aralez Pharmaceuticals Inc., Nevro, Nobilis Health Corp., Stocks on the move, , Read more …
Amicus Therapeutics down 3% on Q1 results
Amicus Therapeutics ( FOLD ) Q1 results : Revenues: $16.7M; Operating Loss: ($56.2M) (-8.1%); Net Loss: ($49.9M) (+9.3%); Loss Per Share: ($0.28) (+28.2%); Quick Assets: $562.5M (+56.9%). More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks…
Amicus Therapeutics beats by $0.08, misses on revenue
Amicus Therapeutics (NASDAQ: FOLD ): Q1 EPS of -$0.28 beats by $0.08 . More news on: Amicus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more …
Institutional Top Ideas Series: Orbimed Advisors
In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of…
Portfolio Review: Continued Market Outperformance In Q1 2018
Following the teaching of Philip Fisher - who is Warren Buffetts mentor - we maintain the core of the Integrated BioSci Investing (IBI) as a long-term oriented growth-investing community. Notwithstanding, we are cognizant of the needs to service our partners, who are in…
Amicus Therapeutics, Inc. (FOLD)